一个IgA血管炎的病例发生在一个用Adalimumab治疗的克罗恩病患者身上
Harujiro Yamamoto1, Yusuke Wakisaka2, Yasuhiro Aoki1
1Department of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Clinical journal of gastroenterology
|February 23, 2026
概括
这项案例研究突出显示,在克罗恩氏病患者接受阿达利姆巴治疗后发生的IgA血管炎. 密切监测IgA血管炎对于服用抗瘤缩因子-α药物的炎症性肠病患者至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
背景情况:
- 克罗恩氏病和IgA血管炎共享诸如腹部和关节疼痛等症状,使诊断复杂化.
- 艾达利穆马布是一种抗瘤亡因子-阿尔法剂,用于治疗克罗恩病.
- 急性桃体炎可以引发免疫反应.
研究的目的:
- 在接受阿达利木马布治疗的克罗恩病患者中,研究急性桃体炎后的IgA血管炎病例.
- 在此背景下,探索可能导致IgA血管炎发展的因素.
- 建议加强对抗TNF-α治疗的炎症性肠病患者的监测方案.
主要方法:
- 案例报告分析.情况报告分析.
- 审查患者的病史和治疗方案.
- 免疫事件和疾病特征的评估.
主要成果:
- 一名患有克罗恩氏病的患者在急性桃体炎后患上了IgA血管炎.
- 抗瘤缩因子-阿尔法疗法,感染和先前存在的疾病可能有助于重叠的免疫因素.
- 由于克罗恩病和IgA血管炎之间的重叠症状,出现了诊断方面的挑战.
结论:
- 患有炎症性肠病的患者服用抗瘤缩因子-α药物需要对潜在的IgA血管炎进行监测,特别是在像桃体炎这样的感染后.
- 了解免疫抑制,感染和自身免疫性疾病的相互作用对于准确的诊断和管理至关重要.
- 这一案例强调了在接受治疗的慢性炎症患者中对二次血管炎的警的重要性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565
Inflammatory Bowel Disease IV: Pharmacological Management
837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
837
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K

